非小细胞肺癌患者细胞学标本EGFR基因突变检测及其临床病理意义

doi:10.3969/j.issn.1004-616x.2016.01.006

癌变·畸变·突变 ›› 2016, Vol. 28 ›› Issue (1): 27-31.doi: 10.3969/j.issn.1004-616x.2016.01.006

非小细胞肺癌患者细胞学标本EGFR基因突变检测及其临床病理意义

吴娟, 杜芸, 王珩, 吴家宁, 赵银环, 王蕊, 张艳, 纪晓坤

河北医科大学第四医院癌检中心, 河北石家庄 050011

收稿日期:2015-06-01 修回日期:2015-10-28 出版日期:2016-01-31 发布日期:2016-01-31
通讯作者: 杜芸Tel;0311-86095393,E-mail:yydd40@126.com E-mail:yydd40@126.com
作者简介:吴娟,E-mail:wujuan199012@163.com。
基金资助:
河北省科技厅项目(14277782D)

Detection of EGFR gene mutation in non-small cell lung cancer and its clinical significance

WU Juan, DU Yun, WANG Heng, WU Jianing, ZHAO Yinhuan, WANG Rui, ZHANG Yan, JI Xiaokun

Cancer Detection Center of the Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei, China

Received:2015-06-01 Revised:2015-10-28 Online:2016-01-31 Published:2016-01-31

摘要/Abstract

摘要： 目的: 探讨细胞学标本在非小细胞肺癌(NSCLC)的诊断及个体化治疗中的临床应用价值。方法: 收集352例新鲜细胞学标本制片后,行常规HE染色;同时选择TTF-1、NapsinA、CK7、CEA、CD56、Syn、P63、CK5/6、WT-1、E-cadherin等抗体对来源不明的肿瘤细胞进行免疫细胞化学标记,并对明确诊断为NSCLC的病例,采用突变扩增阻滞系统(ARMS)检测表皮生长因子受体(EGFR)基因突变情况。结果: 352例患者中,345例有癌细胞。经临床及免疫细胞化学证实345例恶性细胞中,NSCLC有335例,且NSCLC细胞学标本中有302例DNA提取成功,占90.15%(302/335)。EGFR 基因检测结果显示,EGFR 共突变123例,总突变率为40.73%(123/302)。其中,第18、19、20、21外显子的突变率分别为0.99%(3/302)、19.21%(58/302)、0.66%(2/302)和19.87% (60/302); EGFR 18、19、21外显子突变占EGFR 突变总数的98.37%(121/123)显著高于EGFR 20外显子突变(P<0.05)。302例患者中,女性患者EGFR 突变率为54.35% (75/138),明显高于男性患者29.27%(48/164)(P<0.05);非吸烟患者EGFR 的突变率为51.49% (104/202),显著高于吸烟者19%(19/100)(P<0.05)。276例腺癌中EGFR 突变率44.20%(122/276);非腺癌EGFR 突变率4.34%(1/23);腺癌EGFR 突变率明显高于其他类型(P<0.05)。结论: 利用新鲜细胞学标本,结合免疫细胞化学标记和ARMS分子病理技术有助于晚期非小细胞肺癌的诊断,并为表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)个体化治疗提供可靠依据。

关键词: 细胞学标本, 免疫细胞化学, 非小细胞肺癌, 突变扩增阻滞系统, EGFR基因突变检测

Abstract: OBJECTIVE: To investigate the clinical value of cytological specimens in the diagnosis and the individualized treatment of non-small cell lung cancer(NSCLC). METHODS: Cytological specimens were stained with HE and with immunocytochemical method to detect expression of an appropriate set of antibodies (TTF-1 NapsinA,CK7,CEA,CD56,Syn,P63,CK5/6,WT-1,E-cadherin),in tumor cells of unknown origin. The epidermal growth factor receptor(EGFR) gene was detected by the amplification refractory mutation system(ARMS) in NSCLC. RESULTS: In 352 patients,345 cases were found cancer cells on the cytological specimens.According to the clinical history and immunocytochemical staining of the 345 malignant cases,335 were NSCLC cytological samples,and the DNA of 302 NSCLC samples were extracted successfully (satisfaction rate at 90.15%). EGFR mutations were detected in 123 of the 302 specimens (40.73%,123/302) and the frequencies of EGFR mutations in exon18,19,20(T790M),21 were 0.99% (3/302) 19.21%(58/302),0.66%(2/302) and 19.87% (60/302),respectively. Higher frequencies of EGFR mutations were detected in exons 18,19 and 21(98.37%,121/123) than in exon 20(P<0.05). EGFR mutations were more frequently detected in women(54.35%,75/138) than in men (29.27%,48/164)(P<0.05),and in non-smokers (51.49%,104/202) than in smokers 19%(19/100)(P<0.05). Mutations were identified in 44.20%(122/276) cases of adenocarcinoma and 4.34%(1/23) in nonadenocarcinoma. Mutation of EGFR gene in adenocarcinoma was higher than that in non-adenocarcinoma(P<0.05). CONCLUSION: The use of cytological specimens in combination with immuno-cytochemical staining and molecular techniques helps in the diagnosis of advanced cancer and individualized treatment option of NSCLC.

Key words: cytological specimens, immunocytochemical, non-small cell lung cancer, amplification refractory mutation system, EGFR gene mutation detection

中图分类号:

R734.2

吴娟, 杜芸, 王珩, 吴家宁, 赵银环, 王蕊, 张艳, 纪晓坤. 非小细胞肺癌患者细胞学标本EGFR基因突变检测及其临床病理意义[J]. 癌变·畸变·突变, 2016, 28(1): 27-31.

WU Juan, DU Yun, WANG Heng, WU Jianing, ZHAO Yinhuan, WANG Rui, ZHANG Yan, JI Xiaokun. Detection of EGFR gene mutation in non-small cell lung cancer and its clinical significance[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(1): 27-31.

参考文献

[1] Mok TS,Wu YL,Thongprasert S,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med,2009,361(10):947-957.
[2] Govindan R. Proceedings from the 10th annual meeting of molecularly targeted therapy in non-small cell lung cancer[J]. J Thorac Oncol,2010,5(Sup 6) :433-496.
[3] Lynch TJ,Bell DW,Sordella R,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J]. N Engl J Med 2004,350( 21) :2129-2139.
[4] 刘标,周晓军. 非小细胞肺癌个体化治疗的靶向分子检测[J]. 临床与实验病理学杂志,2012,28(8):831-837.
[5] Nagai Y,Miyazawa H,Hu Q,et al.Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system,the peptide nucleic acid-locked nucleic acid PCR clamp[J].Cancer Res,2005,65(16) :7276-7282.
[6] Lee JS,Park K,Kim SW,et al. A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never smokers with advanced or metastatic adenocarcinoma of the lung[R]. San Francisco:13th World Conference on Lung Cance,2009:4.
[7] Tokumo M,Toyooka S,Kiura K,et al. The relationship between epidermal growth factor receptor mutations and clinico-pathologic features in non-small cell lung cancers[J]. Clin Cancer Res,2005,11(3):1167-1173.
[8] Ohba T,Toyokawa G,Kometani T,et al. The mutations of the EGFR and K-RAS genes in resected stage I lung adeno-carcinoma and their clinical significance[J]. Surg Today 2014 44(3):478-486.
[9] Baykara O,Tansarikaya M,Demirkaya A,et al. Association of epidermal growth factor receptor and K-RAS mutations with smoking history in non-small cell lung cancer patients[J]. Exp Ther Med,2013,5(2):495-498.
[10] de Mello RA,Marques DS,Medeiros R,et al. Epidermal growth factor receptor and K-RAS in non-small cell lung cancer-molecular pathways involved and targeted therapies[J]. World J Clin Oncol,2011,2(11):367-376.
[11] 孟加榕,郭以河,张闽峰,等. 肺癌胸水细胞块与组织学EGFR基因扩增检测对比研究[J]. 现代肿瘤医学,2012 20(9):1830-1833.
[12] 王征,武晓楠,穆新林,等. 非小细胞肺癌胸水中癌细胞EGFR基因TK区突变研究[J]. 心肺血管杂志,2009,28(2): 112-116.
[13] 王海彦,庄一平,张晋,等. CT引导下经皮细针穿刺活检检测中晚期肺癌表皮生长因子受体基因突变[J]. 中国介入影像与治疗学,2013,10(1):33-36.

[1]	刘晓霞, 李卫霞, 李志加, 苏镇军, 段晓辉, 韩维文, 王云晓, 贺晓磊, 吕林林, 贾金海. 血清谷胱甘肽过氧化物酶与晚期非小细胞肺癌患者临床病理指标及预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 286-290,295.
[2]	王熙凯, 孟庆贺, 高燕鲁. miR-223-3p通过调控ECT2诱导非小细胞肺癌细胞凋亡的实验研究[J]. 癌变·畸变·突变, 2021, 33(3): 187-192.
[3]	赵子慧, 王绪华. 非小细胞肺癌伴随诊断的研究进展[J]. 癌变·畸变·突变, 2021, 33(1): 66-71,76.
[4]	刘晓霞, 李卫霞, 苏镇军, 贾金海, 段晓辉, 李志加, 贺晓磊, 吕林林, 刘睿, 王云晓. 晚期非小细胞肺癌病理特征及放化疗联合治疗疗效与患者血清超氧化物歧化酶的关系[J]. 癌变·畸变·突变, 2020, 32(5): 350-354.
[5]	应伟, 王兴远, 江波, 周伟. miR-146a多态性与非小细胞肺癌易感性的研究[J]. 癌变·畸变·突变, 2019, 31(3): 222-226.
[6]	朱嘉微, 胡箫, 王希君, 王雅茹, 冯林, 肖汀. Skp1蛋白在非小细胞肺癌组织和外周血中的表达水平及其临床意义[J]. 癌变·畸变·突变, 2019, 31(2): 89-95.
[7]	吴健彬, 江妹, 王玥, 许晶, 岳文涛, 王子彤. 非小细胞肺癌病人源性NOD/SCID小鼠和BALB/c裸鼠移植瘤模型的建立及比较[J]. 癌变·畸变·突变, 2018, 30(2): 114-119.
[8]	郭晓, 王蕊, 吴娟, 纪晓坤, 王珩, 张艳, 马阳, 杜芸. 肺腺癌患者新鲜细胞学标本EGFR基因突变检测及意义[J]. 癌变·畸变·突变, 2018, 30(1): 67-70.
[9]	张静, 滕宇, 赵晓婷, 江妹, 岳文涛. Wnt蛋白生成抑制剂2对非小细胞肺癌细胞迁移与侵袭能力的影响[J]. 癌变·畸变·突变, 2017, 29(4): 245-250.
[10]	宋杰, 李萍, 于雪新, 冯林, 高燕宁, 肖汀. Syntenin在非小细胞肺癌中的表达及其与患者总生存期的关系[J]. 癌变·畸变·突变, 2017, 29(2): 102-105.
[11]	李超, 倪娟, 徐伟江, 汪旭. miR-22、miR-34a与叶酸介导的一碳代谢在非小细胞肺癌和肝细胞癌中的调控作用[J]. 癌变·畸变·突变, 2016, 28(4): 317-320.
[12]	翟晓然, 江妹, 赵晓婷, 顾勐, 岳文涛. PFTK1在人非小细胞肺癌中的表达及临床意义[J]. 癌变·畸变·突变, 2016, 28(3): 231-235.
[13]	凌兵,冯林,程书钧. DENND2D通过调控PARP1对非小细胞肺癌细胞系H1299中顺铂细胞毒性的影响[J]. 癌变·畸变·突变, 2013, 25(2): 87-90.
[14]	孙国贵,张钧,胡万宁. Survivin和Cox-2蛋白与非小细胞肺癌危险因素的系统评价[J]. , 2012, 24(3): 199-204.
[15]	王凤云，张艳桥*，罗明，武云，李鹏，李志伟，孙伟. p-Stat3、VEGF-C和MMP-2在非小细胞肺癌中的表达及其与淋巴结转移的关系[J]. , 2011, 23(2): 107-110.

非小细胞肺癌患者细胞学标本EGFR基因突变检测及其临床病理意义

Detection of EGFR gene mutation in non-small cell lung cancer and its clinical significance

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价